ContactContact

2018 sales of the Galenica Group

Tuesday, 22 January 2019

Solid sales growth and confirmation of 2018 earnings guidance

Galenica increased its consolidated net sales by 0.8% to CHF 3,165.5 million in 2018. This solid performance in the current market environment was achieved thanks to organic growth in all Business sectors and the expansion of the pharmacy network. The Retail Business sector performed particularly well, with an increase in sales of 3.1%. Growth was hampered by additional and higher than originally announced price reduction measures for medications by the authorities.

The company also achieved sustainable improvements in profitability in 2018. The management of the Galenica Group is therefore confident of achieving the announced EBIT growth (excluding the effects of IAS 19) for financial year 2018. Consequently, the outlook regarding proposal of a dividend of at least at the same level as the prior year to the Annual General Meeting in 2019 is unchanged.

Net sales Galenica Group 2018

 
 

(in million CHF)

2018

20171)

Change

Health & Beauty segment

1,524.8

1,478.8

+3.1%

- Retail

1,430.5

1,387.3

+3.1%

- Products & Brands

91.7

89.3

+2.7%

Services segment

2,370.3

2,362.4

+0.3%

Corporate and eliminations

(729.6)

(-700.0)


Galenica Group

3,165.5

3,141.2

+0.8%

1) Sales figures for 2017 have been restated in line with the new IFRS 15 accounting standards, which came into effect on 1 January 2018.

Contact

Galenica Ltd.

Media
Untermattweg 8
3027 Bern

Tel. +41 58 852 85 17
Fax +41 58 852 85 58

Contact

Galenica Ltd.

Investors
Untermattweg 8
3027 Bern

Tel. +41 58 852 85 29
Fax +41 58 852 85 35